Elan Prialt NDA Awaits Longer-Term Data In Chronic Pain
Executive Summary
Elan is planning a long-term study of the chronic pain treatment Prialt (ziconotide) to supplement its pending NDA, the company told a Feb. 4 conference call
You may also be interested in...
Elan Prialt Clears FDA; Half Of Projected Market Does Not Have Delivery Pump
Elan estimates that more than half of the 120,000 potential users of its non-opioid analgesic Prialt do not already possess an internal drug delivery pump expected to be used in ziconotide administrations
Elan Prialt Clears FDA; Half Of Projected Market Does Not Have Delivery Pump
Elan estimates that more than half of the 120,000 potential users of its non-opioid analgesic Prialt do not already possess an internal drug delivery pump expected to be used in ziconotide administrations
Elan Pinning 2005 Profitability Hopes On Antegren, Prialt Launches
Elan expects to return to profitability in 2005 with the potential launches of Antegren for multiple sclerosis and Crohn's disease and Prialt for chronic pain